Joint Winners for 2013 Aspiring Director Award

Joint Winners for 2013 Aspiring Director Award

For the first time in the award’s 15 year history the Canterbury Branch of the Institute of Directors’ Aspiring Director Award has been awarded to joint winners.

Elizabeth Hopkins and Michael Lay have been announced as joint winners for the 2013 Aspiring Director Award. Both applicants equally impressed the Selection Committee with their career experience, business skills and understanding of governance.

Selected from an impressive group of applicants, Elizabeth and Michael both receive $1,500 towards an Institute of Directors (IoD) Director Development course, a year’s complimentary membership of the IoD, a year’s internship with the one of the CCHL boards and mentoring with an experienced director.

"I'm pleased to be able to present this award to two very talented aspiring directors,” said Dr William Whittaker. “The Canterbury branch of the IoD pioneered the Aspiring Director Award, and it's a measure of its success that it is now offered by IoD branches nationwide. The award has been instrumental in bringing fresh perspectives into the boardroom and offers a step on the ladder for a new generation of directors."

Elizabeth comes from a strong scientific background with international business experience. She has held senior management positions and is committed to developing her governance career. She sees herself adding value to a board by the business acumen she has developed through working in some highly challenging situations.

Michael runs a rural based accountancy practice. He is actively involved in governance of community organisations, including chairing both of the boards of trustees of Christchurch Girls High School and Selwyn Sports Trust. While he has considerable practical experience in governance he is looking forward to attending the IoD’s Governance Development Programme (GDP) next year.

“CCHL is fully supportive of these awards and sees great value in nurturing the next generation of directors. Having diversity around the board table, whether its gender, ethnicity, age or professional background, will benefit the success of any company and therefore the shareholders,” said Bruce Irvine, chair of CCHL.

“Thank you also to the chair and boards of EcoCentral and Connetics for playing an important role in providing these intern opportunities,” added Mr Irvine.

Elizabeth and Michael were presented with the Award by the IoD Chief Executive, Dr William Whittaker at the IoD Canterbury branch function and dinner last night.

-Ends-

Canterbury Branch Manager Email: canterbury.branch@iod.org.nz
22 October 2013

Pacific Edge signs agreement with America’s Choice Provider Network to expand access to Cxbladder in the US

Pacific Edge’s has signed an agreement with America’s Choice Provider Network (ACPN) for access to Cxbladder. ACPN offers a medical network solution for more than 14 million Americans through its client base consisting of insurance carriers, third party administrators, health and welfare funds, employer groups and self-insured health plans. This follows Pacofic Edge’s recent announcement of the agreement with FedMed providing 40 million Americans with access to Cxbladder1.

Pacific Edge Chief Executive Officer David Darling says agreements with FedMed and now ACPN form key elements in the commercial roll-out of Cxbaldder in the US.

Pacific Edge through its wholly owned subsidiary Pacific Edge Diagnostics USA (PEDUSA) has already achieved the first commercial sales of Cxbladder in the US2 and has processed samples collected using its proprietary Urine Sample System at its custom built laboratory in Hershey, Pennsylvania.

“These provider networks provide patients access to healthcare services and technology by contracting with providers and payers on a national basis. These two recent agreements signed with FedMed and now ACPN will give millions of Americans access to Cxbladder and its positive benefits as a quick, cost effective, non-invasive and highly accurate cancer detection test that is particularly appealing to US healthcare professionals, patients, and insurers,” says Jackie Walker, Chief Executive Officer of PEDUSA

“PEDUSA’s sales and marketing team is focussed on the clinicians who are treating the largest number of bladder cancer patients. They are also focussed on the large commercial payers and the Centre for Medicare and Medicaid Services, (CMS), which provides healthcare insurance for 100 million people or nearly a third of the American population. Other key sales targets include Integrated Healthcare Systems, comprising many providers and facilities while offering a wide variety of health insurance plans, the Veterans Administration (VA), and Large Urology Groups (LUGS), who are the point of contact for many patients presenting with haematuria (blood in the urine) which is an early indicator of possible bladder cancer”.”

More than one million Americans will undergo medical investigation this year for potential bladder cancer at an estimated cost of $US1 billion. Bladder cancer is one of the most expensive cancers to treat. The very high recurrence of this disease, some patients receive expensive monitoring for the rest of their lives,cause bladder cancer to have the highest total medical costs of any cancer from detection to death. In the US, the total medical cost approaches $US220,000 per patient.
ends

© Scoop Media